What is DA Davidson’s Estimate for PBH FY2025 Earnings?

Prestige Consumer Healthcare Inc. (NYSE:PBH) – Equities research analysts at DA Davidson increased their FY2025 earnings per share (EPS) estimates for shares of Prestige Consumer Healthcare in a research note issued on Monday, February 10th. DA Davidson analyst L. Weiser now anticipates that the company will post earnings per share of $4.50 for the year, up from their previous estimate of $4.46. DA Davidson currently has a “Buy” rating and a $104.00 price objective on the stock. The consensus estimate for Prestige Consumer Healthcare’s current full-year earnings is $4.50 per share. DA Davidson also issued estimates for Prestige Consumer Healthcare’s Q4 2025 earnings at $1.30 EPS.

A number of other research firms have also recently weighed in on PBH. Raymond James raised shares of Prestige Consumer Healthcare to a “moderate buy” rating in a research note on Thursday, December 19th. Canaccord Genuity Group boosted their target price on Prestige Consumer Healthcare from $93.00 to $100.00 and gave the stock a “buy” rating in a research report on Friday, February 7th. Sidoti cut Prestige Consumer Healthcare from a “buy” rating to a “neutral” rating and set a $90.00 price target for the company. in a research report on Monday, December 9th. Finally, StockNews.com raised shares of Prestige Consumer Healthcare from a “hold” rating to a “buy” rating in a research note on Friday, January 24th. Two investment analysts have rated the stock with a hold rating and three have given a buy rating to the company. According to data from MarketBeat, Prestige Consumer Healthcare currently has a consensus rating of “Moderate Buy” and a consensus target price of $92.50.

Prestige Consumer Healthcare Stock Performance

NYSE PBH opened at $86.03 on Tuesday. The company has a current ratio of 3.68, a quick ratio of 2.10 and a debt-to-equity ratio of 0.56. Prestige Consumer Healthcare has a 12-month low of $62.35 and a 12-month high of $88.36. The stock has a market capitalization of $4.25 billion, a price-to-earnings ratio of 20.15, a PEG ratio of 2.43 and a beta of 0.50. The business’s 50 day moving average is $79.28 and its two-hundred day moving average is $75.63.

Prestige Consumer Healthcare (NYSE:PBH) last announced its quarterly earnings data on Thursday, February 6th. The company reported $1.22 EPS for the quarter, topping analysts’ consensus estimates of $1.18 by $0.04. Prestige Consumer Healthcare had a net margin of 19.13% and a return on equity of 12.36%.

Institutional Trading of Prestige Consumer Healthcare

Several hedge funds and other institutional investors have recently bought and sold shares of PBH. Northwestern Mutual Wealth Management Co. grew its position in shares of Prestige Consumer Healthcare by 562.3% in the second quarter. Northwestern Mutual Wealth Management Co. now owns 510 shares of the company’s stock valued at $35,000 after purchasing an additional 433 shares during the period. SG Americas Securities LLC purchased a new stake in Prestige Consumer Healthcare in the 3rd quarter valued at about $364,000. GAMMA Investing LLC increased its stake in shares of Prestige Consumer Healthcare by 49.9% during the 3rd quarter. GAMMA Investing LLC now owns 1,163 shares of the company’s stock valued at $84,000 after acquiring an additional 387 shares during the last quarter. Inspire Investing LLC lifted its holdings in shares of Prestige Consumer Healthcare by 11.7% during the 3rd quarter. Inspire Investing LLC now owns 5,702 shares of the company’s stock worth $411,000 after acquiring an additional 599 shares during the period. Finally, Exchange Traded Concepts LLC boosted its position in shares of Prestige Consumer Healthcare by 6.3% in the third quarter. Exchange Traded Concepts LLC now owns 22,801 shares of the company’s stock worth $1,644,000 after acquiring an additional 1,343 shares during the last quarter. 99.95% of the stock is owned by hedge funds and other institutional investors.

Insider Activity

In related news, CEO Ronald M. Lombardi sold 10,875 shares of the company’s stock in a transaction that occurred on Tuesday, November 19th. The shares were sold at an average price of $82.60, for a total transaction of $898,275.00. Following the transaction, the chief executive officer now owns 320,952 shares of the company’s stock, valued at approximately $26,510,635.20. This represents a 3.28 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Company insiders own 1.60% of the company’s stock.

About Prestige Consumer Healthcare

Prestige Consumer Healthcare Inc, together with its subsidiaries, develops, manufactures, markets, distributes, and sells over-the-counter (OTC) health and personal care products in the United States and internationally. The company operates in two segments, North American OTC Healthcare and International OTC Healthcare.